The volume of new drugs entering the Russian market is constantly growing. It means that the number of clinical trials of drugs, performed in Russia is growing too, for before a new drug comes to the market, it should pass clinical trials.
In the last five years the number of clinical trials performed in Russia has increased by over 40 per cent. In 2011 571 trial was conducted, in 2014 – 750 trials, in 2015 – 804 trials. The growth in 2014 and 2015 was 7.2 per cent, and in 2015 – 42.8 per cent. This information was provided by Oleg Salagay, Director of Public Health and Communications Department at the Ministry of Healthcare of the Russian Federation at a RIA-Novosti press-conference.
Within the federal target project “Development of pharmaceutical and medical industry in Russia until 2020 and further” in 2015 126 contracts were executed. Currently, 65 projects development and manufacture projects are ongoing, including projects related to pharmaceutical substances, and 320 projects for development of novel drugs on socially significant diseases. According to Oleg Sagalay, thanks to legislation improvement and innovative international approaches, the number of refusals is minimized while requirements to quality, efficacy and safety of drugs remain unchanged. The share of positive conclusion for international multicenter clinical trials has increased from 77.5% in 2012 to 96.4% in the first quarter of 2016.